Companies: 10,795·Total market cap: $144.5T
LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc.

LENZNASDAQHealthcare● Active
$7.01
$-0.00(-0.04%)
Market Cap$219709645
P/E Ratio—
52W High$50.4
52W Low$6.61
Overview
Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

LENZ Therapeutics, Inc. (LENZ) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · LENZ · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-3.60lenz eps ttm · lenz earnings per shareEarnings history
PE Ratio (TTM)—lenz pe ratio ttm · lenz price to earningsPE Ratio deep dive
Revenue (TTM)$21.0Mlenz revenue ttm · lenz annual revenueFull revenue history
Dividend Yield89.01%does lenz pay dividends · lenz dividend yieldDividend history
Shares Outstanding28.8Mlenz shares outstanding · lenz floatShares outstanding history
Next EarningsJul 29, 2026Est.lenz earnings date · lenz next earningsEarnings history

Explore LENZ Therapeutics, Inc. Data

lenz stock data · financials
Market Cap$219.7Mlenz market cap · lenz valuation
Analyst Forecast$12 · Buy
Dividends89.01%does lenz therapeutics, inc. pay dividends · lenz dividend yield
Revenue$19.1Mlenz therapeutics, inc. annual revenue · lenz revenue
EarningsEPS $-2.85-21.79%lenz earnings · lenz eps
PE Ratio—lenz pe ratio · lenz price to earnings

Financial Snapshot

Full Financials
FY 2025Revenue$19.1M
202320242025
lenz therapeutics, inc. revenue · lenz revenue 2025
FY 2025Net Income-$82.1M▼ 65.02% YoY
202320242025
lenz therapeutics, inc. net income · lenz profit 2025
FY 2025EPS$-2.85▼ 21.79% YoY
202320242025
lenz eps · lenz therapeutics, inc. earnings per share 2025
TTM:Revenue: $21.0MNet Income: -$109.0MEPS: $-3.60View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy5 analystsis lenz a buy · lenz analyst rating
Strong Buy
0
Buy
4
Hold
1
Sell
0
Strong Sell
0
12-Month Price Target
$12.00Low
$7.01Current
$12.00Avg Target71.25% upside
$12.00High
lenz price target · lenz 12 month forecast

Total: 5 · Buy rate: 80.0%

The LENZ analyst consensus is Buy, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month price target is $12.00, representing +71.25% upside from the current price of $7.01.

Stock Performance

Full History
1D-0.14%
1W+0.00%
1M-30.42%
3M-40.02%
YTD-56.25%
1Y-77.58%
5Y-92.01%

About LENZ Therapeutics, Inc.

CEOEvert Schimmelpennink
IPO DateMar 22, 2024
Employees6
CountryUS
Websitelenz-tx.com

LENZ Therapeutics, Inc. a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which…

BiotechnologyHealthcareNASDAQUS

what is lenz therapeutics, inc. · lenz stock overview · lenz therapeutics, inc. company profile · who is lenz therapeutics, inc. ceo · lenz NASDAQ · lenz therapeutics, inc. headquarters · lenz therapeutics, inc. business segments

About Stock Overview & Key Data

LENZ Therapeutics, Inc. (LENZ) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Mar 22, 2024. As of the latest trading session, LENZ stock price is $7.01, with a market capitalization of $219.7M. The stock has returned -77.58% over the past 12 months and -56.25% year-to-date.

According to 5 Wall Street analysts, the consensus rating for LENZ Therapeutics, Inc. stock is Buy, with an average 12-month price target of $12.00. In fiscal year 2025, LENZ Therapeutics, Inc. reported revenue of $19.1M and net income of -$82.1M. For detailed data — including LENZ Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, LENZ Therapeutics, Inc. (LENZ) stock price is $7.01. The stock is traded on NASDAQ under the ticker symbol LENZ. The 52-week range is $6.61 – $50.40.

LENZ stock priceLENZ quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice